Keyphrases
Anthrax Vaccine
34%
Antibody Response
64%
AZD1222
35%
Bacillus Anthracis
21%
Blood Samples
12%
BNT162b2
52%
BNT162b2 Vaccine
16%
Booster Dose
23%
Cellular Immune Response
17%
Cellular Response
13%
Chad
24%
ChAdOx1
13%
ChAdOx1 nCoV-19
92%
ChAdOx1 nCoV-19 Vaccine
24%
Confidence Interval
17%
Convalescent
13%
COVID-19
89%
COVID-19 Vaccine
54%
Enzyme-linked Immunosorbent Assay (ELISA)
12%
Ferret
26%
Geometric Mean
28%
Geometric Mean Concentration
13%
Humoral Immune Response
21%
Immune Response
33%
Immunogenicity
98%
Influenza Virus
22%
Monkeypox Virus
17%
Multiplex Immunoassay
16%
Neurotoxin
15%
Neutralizing Antibodies
31%
Older People
12%
Pertussis
21%
Prime-boost
13%
Randomized Controlled Trial
43%
Randomized Trial
26%
Ratio of Means
23%
Reactogenicity
36%
Revaccination
13%
SARS-CoV-2 Infection
21%
SARS-CoV-2 Vaccine
17%
Second Dose
29%
Spike Protein
12%
T Cell Response
22%
Third Dose
28%
Two-dose
35%
Vaccination
45%
Vaccine Effectiveness
16%
Vaccine Response
24%
Virus
34%
Virus Neutralization
16%
Immunology and Microbiology
Adoptive Immunity
26%
Anthrax Vaccine Adsorbed
29%
Antibody Response
62%
Antibody Titer
19%
Bacillus Anthracis
16%
Bacterium Antibody
10%
Booster Dose
22%
COVID-19
56%
Defective Interfering Particle
10%
ELISA
14%
Haemophilus Influenzae Type B
11%
Hemagglutinin
13%
Humoral Immunity
32%
Immune Response
42%
Immunoassay
19%
Immunogenicity
68%
Immunoglobulin G
25%
Influenza
23%
Influenza Vaccine
12%
Influenza Virus
23%
Influenzavirus A
12%
Lethal Gene
9%
Lineages
10%
Low Drug Dose
14%
Macaca fascicularis
10%
Meningococcal Vaccine
15%
Modified Vaccinia Ankara
7%
Monkeypox Virus
21%
Mustela Putorius Furo
27%
Neutralization
32%
Neutralizing Antibody
27%
Omicron Coronavirus Variant
10%
Peptides
8%
Pertactin
8%
Pertussis Toxin
17%
Plaque-Forming Unit
7%
Serotype
13%
Serum (Blood)
7%
Severe Acute Respiratory Syndrome Coronavirus 2
100%
Spike
43%
T Cell
24%
Tetanus Vaccine
10%
Vaccine Adjuvant
10%
Viral Disease
12%
Viral Protein
13%
Viral Shedding
10%
Viral Vector
11%
Virus
32%
Virus Antigen
14%
Virus Neutralization
8%
Medicine and Dentistry
Adaptive Immunity
6%
Adverse Event
11%
Antibody Generation
6%
Antibody Response
46%
Arm
7%
Booster Dose
34%
Cellular Immunity
22%
Clinical Trial
19%
COVID-19
47%
COVID-19 Vaccination
14%
COVID-19 Vaccine
48%
Cross Sectional Study
5%
Diseases
9%
Drug Dose Regimen
9%
Enzyme Linked Immunosorbent Assay
15%
Group Trial
5%
Humoral Immunity
23%
Immune Response
33%
Immunoassay
11%
Immunogenicity
70%
Infection
61%
Influenza Vaccine
5%
Interim Analysis
6%
Medicine
11%
Meningococcus Vaccine
5%
Messenger RNA
30%
mRNA Vaccine
11%
Neisseria meningitidis
5%
Neutralization
21%
Neutralizing Antibody
30%
Noninferiority Trial
10%
Nucleic Acid Amplification
10%
Pertussis
7%
Phagocytosis
5%
Pooled Analysis
5%
Primary Infection
5%
Quantitative Assay
5%
Randomized Controlled Trial
31%
Reactogenicity
19%
Severe Acute Respiratory Syndrome Coronavirus 2
84%
Single Drug Dose
26%
T Cell
13%
T-Cell Response
12%
Vaccine Adjuvant
10%
Vaccine Efficacy
14%
Viral Protein
10%
Virus
5%
Virus Neutralization
7%
Virus Particle
5%
Virus Vector
11%